

SECOND REGULAR SESSION

# HOUSE BILL NO. 2050

## 95TH GENERAL ASSEMBLY

---

INTRODUCED BY REPRESENTATIVES ROORDA (Sponsor), NOLTE, SCHIEFFER, GRILL,  
MEADOWS AND CORCORAN (Co-sponsors).

4897L.011

D. ADAM CRUMBLISS, Chief Clerk

---

### AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with a penalty provision.

---

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 17 (g) Alpha-methylfentanyl;
- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;

- 53 (qq) PEPAP;  
54 (rr) Phenadoxone;  
55 (ss) Phenampromide;  
56 (tt) Phenomorphan;  
57 (uu) Phenoperidine;  
58 (vv) Piritramide;  
59 (ww) Proheptazine;  
60 (xx) Properidine;  
61 (yy) Propiram;  
62 (zz) Racemoramide;  
63 (aaa) Thiofentanyl;  
64 (bbb) Tilidine;  
65 (ccc) Trimeperidine;  
66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers  
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers  
68 is possible within the specific chemical designation:
- 69 (a) Acetorphine;  
70 (b) Acetyldihydrocodeine;  
71 (c) Benzylmorphine;  
72 (d) Codeine methylbromide;  
73 (e) Codeine-N-Oxide;  
74 (f) Cyprenorphine;  
75 (g) Desomorphine;  
76 (h) Dihydromorphine;  
77 (i) Drotebanol;  
78 (j) Etorphine (except hydrochloride salt);  
79 (k) Heroin;  
80 (l) Hydromorphanol;  
81 (m) Methyldesorphine;  
82 (n) Methyldihydromorphine;  
83 (o) Morphine methylbromide;  
84 (p) Morphine methylsulfonate;  
85 (q) Morphine-N-Oxide;  
86 (r) Myrophine;  
87 (s) Nicocodeine;  
88 (t) Nicomorphine;

- 89 (u) Normorphine;
- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) Alpha-ethyltryptamine;
- 110 (o) Alpha-methyltryptamine;
- 111 (p) Bufotenine;
- 112 (q) Diethyltryptamine;
- 113 (r) Dimethyltryptamine;
- 114 (s) 5-methoxy-N,N-diisopropyltryptamine;
- 115 (t) Ibogaine;
- 116 (u) Lysergic acid diethylamide;
- 117 (v) Marijuana or marihuana;
- 118 (w) Mescaline;
- 119 (x) Parahexyl;
- 120 (y) Peyote, to include all parts of the plant presently classified botanically as Lophophora
- 121 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
- 122 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
- 123 its seed or extracts;
- 124 (z) N-ethyl-3-piperidyl benzilate;

- 125 (aa) N-methyl-3-piperidyl benzilate;
- 126 (bb) Psilocybin;
- 127 (cc) Psilocyn;
- 128 (dd) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
- 129 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
- 130 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
- 131 isomers with similar chemical structure and pharmacological activity to those substances
- 132 contained in the plant, such as the following:
- 133 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 134 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 135 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 136 d. Any compounds of these structures, regardless of numerical designation of atomic
- 137 positions covered;
- 138 (ee) Ethylamine analog of phencyclidine;
- 139 (ff) Pyrrolidine analog of phencyclidine;
- 140 (gg) Thiophene analog of phencyclidine;
- 141 (hh) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 142 (ii) Salvia divinorum;
- 143 (jj) Salvinorin A;
- 144 **(kk) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol);**
- 145 **(ll) (dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-**
- 146 **yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);**
- 147 **(mm) 1-Pentyl-3-(1-naphthoyl)indole;**
- 148 **(nn) 1-Butyl-3-(1-naphthoyl)indole;**
- 149 (5) Any material, compound, mixture or preparation containing any quantity of the
- 150 following substances having a depressant effect on the central nervous system, including their
- 151 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
- 152 isomers is possible within the specific chemical designation:
- 153 (a) Gamma-hydroxybutyric acid;
- 154 (b) Mecloqualone;
- 155 (c) Methaqualone;
- 156 (6) Any material, compound, mixture or preparation containing any quantity of the
- 157 following substances having a stimulant effect on the central nervous system, including their
- 158 salts, isomers and salts of isomers:
- 159 (a) Aminorex;
- 160 (b) N-benzylpiperazine;

- 161 (c) Cathinone;
- 162 (d) Fenethylamine;
- 163 (e) Methcathinone;
- 164 (f) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 165 (g) N-ethylamphetamine;
- 166 (h) N,N-dimethylamphetamine;
- 167 (7) A temporary listing of substances subject to emergency scheduling under federal law
- 168 shall include any material, compound, mixture or preparation which contains any quantity of the
- 169 following substances:
- 170 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
- 171 salts and salts of isomers;
- 172 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
- 173 optical isomers, salts and salts of isomers;
- 174 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
- 175 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
- 176 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 177 3. The department of health and senior services shall place a substance in Schedule II
- 178 if it finds that:
- 179 (1) The substance has high potential for abuse;
- 180 (2) The substance has currently accepted medical use in treatment in the United States,
- 181 or currently accepted medical use with severe restrictions; and
- 182 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 183 4. The controlled substances listed in this subsection are included in Schedule II:
- 184 (1) Any of the following substances whether produced directly or indirectly by extraction
- 185 from substances of vegetable origin, or independently by means of chemical synthesis, or by
- 186 combination of extraction and chemical synthesis:
- 187 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
- 188 opiate, excluding apomorphine, thebaine-derived butorphanol, dextroproprium, nalbuphine,
- 189 nalmefene, naloxone and naltrexone, and their respective salts but including the following:
- 190 a. Raw opium;
- 191 b. Opium extracts;
- 192 c. Opium fluid;
- 193 d. Powdered opium;
- 194 e. Granulated opium;
- 195 f. Tincture of opium;
- 196 g. Codeine;

- 197 h. Ethylmorphine;  
198 i. Etorphine hydrochloride;  
199 j. Hydrocodone;  
200 k. Hydromorphone;  
201 l. Metopon;  
202 m. Morphine;  
203 n. Oxycodone;  
204 o. Oxymorphone;  
205 p. Thebaine;  
206 (b) Any salt, compound, derivative, or preparation thereof which is chemically  
207 equivalent or identical with any of the substances referred to in this subdivision, but not  
208 including the isoquinoline alkaloids of opium;  
209 (c) Opium poppy and poppy straw;  
210 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and  
211 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical  
212 with any of these substances, but not including decocainized coca leaves or extractions which  
213 do not contain cocaine or ecgonine;  
214 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid  
215 or powder form which contains the phenanthrene alkaloids of the opium poppy);  
216 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts  
217 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within  
218 the specific chemical designation, dextrophan and levopropoxyphene excepted:  
219 (a) Alfentanil;  
220 (b) Alphaprodine;  
221 (c) Anileridine;  
222 (d) Bezitramide;  
223 (e) Bulk dextropropoxyphene;  
224 (f) Carfentanil;  
225 (g) Butyl nitrite;  
226 (h) Dihydrocodeine;  
227 (i) Diphenoxylate;  
228 (j) Fentanyl;  
229 (k) Isomethadone;  
230 (l) Levo-alphaacetylmethadol;  
231 (m) Levomethorphan;  
232 (n) Levorphanol;

- 233 (o) Metazocine;
- 234 (p) Methadone;
- 235 (q) Meperidine;
- 236 (r) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 237 (s) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic  
238 acid;
- 239 (t) Pethidine (meperidine);
- 240 (u) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 241 (v) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 242 (w) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 243 (x) Phenazocine;
- 244 (y) Piminodine;
- 245 (z) Racemethorphan;
- 246 (aa) Racemorphan;
- 247 (bb) Remifentanyl;
- 248 (cc) Sufentanyl;
- 249 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
250 following substances having a stimulant effect on the central nervous system:
- 251 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 252 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 253 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 254 (d) Phenmetrazine and its salts;
- 255 (e) Methylphenidate;
- 256 (4) Any material, compound, mixture, or preparation which contains any quantity of the  
257 following substances having a depressant effect on the central nervous system, including its salts,  
258 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers  
259 is possible within the specific chemical designation:
- 260 (a) Amobarbital;
- 261 (b) Glutethimide;
- 262 (c) Pentobarbital;
- 263 (d) Phencyclidine;
- 264 (e) Secobarbital;
- 265 (5) Any material or compound which contains any quantity of nabilone;
- 266 (6) Any material, compound, mixture, or preparation which contains any quantity of the  
267 following substances:
- 268 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;

- 269 (b) Immediate precursors to phencyclidine (PCP):  
270 a. 1-phenylcyclohexylamine;  
271 b. 1-piperidinocyclohexanecarbonitrile (PCC).  
272 5. The department of health and senior services shall place a substance in Schedule III  
273 if it finds that:  
274 (1) The substance has a potential for abuse less than the substances listed in Schedules  
275 I and II;  
276 (2) The substance has currently accepted medical use in treatment in the United States;  
277 and  
278 (3) Abuse of the substance may lead to moderate or low physical dependence or high  
279 psychological dependence.  
280 6. The controlled substances listed in this subsection are included in Schedule III:  
281 (1) Any material, compound, mixture, or preparation which contains any quantity of the  
282 following substances having a potential for abuse associated with a stimulant effect on the  
283 central nervous system:  
284 (a) Benzphetamine;  
285 (b) Chlorphentermine;  
286 (c) Clortermine;  
287 (d) Phendimetrazine;  
288 (2) Any material, compound, mixture or preparation which contains any quantity or salt  
289 of the following substances or salts having a depressant effect on the central nervous system:  
290 (a) Any material, compound, mixture or preparation which contains any quantity or salt  
291 of the following substances combined with one or more active medicinal ingredients:  
292 a. Amobarbital;  
293 b. Secobarbital;  
294 c. Pentobarbital;  
295 (b) Any suppository dosage form containing any quantity or salt of the following:  
296 a. Amobarbital;  
297 b. Secobarbital;  
298 c. Pentobarbital;  
299 (c) Any substance which contains any quantity of a derivative of barbituric acid or its  
300 salt;  
301 (d) Chlorhexadol;  
302 (e) Embutramide;

- 303 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in  
304 a drug product for which an application has been approved under Section 505 of the federal  
305 Food, Drug, and Cosmetic Act;
- 306 (g) Ketamine, its salts, isomers, and salts of isomers;
- 307 (h) Lysergic acid;
- 308 (i) Lysergic acid amide;
- 309 (j) Methyprylon;
- 310 (k) Sulfondiethylmethane;
- 311 (l) Sulfonethylmethane;
- 312 (m) Sulfonmethane;
- 313 (n) Tiletamine and zolazepam or any salt thereof;
- 314 (3) Nalorphine;
- 315 (4) Any material, compound, mixture, or preparation containing limited quantities of any  
316 of the following narcotic drugs or their salts:
- 317 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
318 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid  
319 of opium;
- 320 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
321 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized  
322 therapeutic amounts;
- 323 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
324 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an  
325 isoquinoline alkaloid of opium;
- 326 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
327 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic  
328 ingredients in recognized therapeutic amounts;
- 329 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more  
330 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in  
331 recognized therapeutic amounts;
- 332 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters  
333 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic  
334 ingredients in recognized therapeutic amounts;
- 335 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per  
336 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more  
337 active nonnarcotic ingredients in recognized therapeutic amounts;

338 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one  
339 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic  
340 amounts;

341 (5) Any material, compound, mixture, or preparation containing any of the following  
342 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

343 (6) Anabolic steroids. Any drug or hormonal substance, chemically and  
344 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and  
345 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is  
346 expressly intended for administration through implants to cattle or other nonhuman species and  
347 which has been approved by the Secretary of Health and Human Services for that administration.  
348 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall  
349 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the  
350 meaning of this [paragraph] **subdivision**. Unless specifically excepted or unless listed in another  
351 schedule, any material, compound, mixture or preparation containing any quantity of the  
352 following substances, including its salts, esters and ethers:

- 353 (a)  $3\beta,17$ -dihydroxy- $5\alpha$ -androsterane;  
354 (b)  $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androsterane;  
355 (c)  $5\alpha$ -androsteran- $3,17$ -dione;  
356 (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androst-1-ene);  
357 (e) 1-androstenediol ( $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androst-1-ene);  
358 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);  
359 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);  
360 (h) 1-androstenedione ( $[5\alpha]$ -androst-1-en- $3,17$ -dione);  
361 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);  
362 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);  
363 (k) Bolasterone ( $7\alpha, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-en-3-one);  
364 (l) Boldenone ( $17\beta$ -hydroxyandrost-1,4,-diene-3-one);  
365 (m) Calusterone ( $7\beta, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-en-3-one);  
366 (n) Clostebol (4-chloro- $17\beta$ -hydroxyandrost-4-en-3-one);  
367 (o) Dehydrochloromethyltestosterone (4-chloro- $17\beta$ -hydroxy- $17\alpha$ -methyl-androst-1,4-  
368 dien-3-one);  
369 (p)  $\Delta 1$ -dihydrotestosterone (a.k.a. '1-testosterone')( $17\beta$ -hydroxy- $5\alpha$ -androst-1-en-3-one);  
370 (q) 4-dihydrotestosterone ( $17\beta$ -hydroxy-androstan-3-one);  
371 (r) Drostanolone ( $17\beta$ -hydroxy- $2\alpha$ -methyl- $5\alpha$ -androsteran-3-one);  
372 (s) Ethylestrenol ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-ene);  
373 (t) Fluoxymesterone (9-fluoro- $17\alpha$ -methyl- $11\beta,17\beta$ -dihydroxyandrost-4-en-3-one);

- 374 (u) Formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one);  
375 (v) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-furazan);  
376 (w) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;  
377 (x) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);  
378 (y) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);  
379 (z) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5-androstan-3-one);  
380 (aa) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one);  
381 (bb) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);  
382 (cc) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);  
383 (dd) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);  
384 (ee) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one);  
385 (ff) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstan-3-one);  
386 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene);  
387 (hh) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-3-  
388 one);  
389 (ii) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);  
390 (jj) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9-11-trien-3-one);  
391 (kk) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);  
392 (ll) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
393 (mm) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-  
394 3-one) (a.k.a. '17- $\alpha$ -methyl-1-testosterone');  
395 (nn) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);  
396 (oo) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);  
397 (pp) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);  
398 (qq) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);  
399 (rr) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);  
400 (ss) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
401 (tt) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
402 (uu) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);  
403 (vv) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);  
404 (ww) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
405 (xx) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
406 (yy) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androstan-3-one);  
407 (zz) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
408 (aaa) Oxymethalone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-  
409 one);

- 410 (bbb) Stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-2-eno[3,2-c]-pyrazole);  
411 (ccc) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-en-3-one);  
412 (ddd) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);  
413 (eee) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);  
414 (fff) Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4,9,11-trien-3-one);  
415 (ggg) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);  
416 (hhh) Any salt, ester, or ether of a drug or substance described or listed in this  
417 subdivision, except an anabolic steroid which is expressly intended for administration through  
418 implants to cattle or other nonhuman species and which has been approved by the Secretary of  
419 Health and Human Services for that administration;
- 420 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a  
421 United States Food and Drug Administration approved drug product;
- 422 (8) The department of health and senior services may except by rule any compound,  
423 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions  
424 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to  
425 195.320 if the compound, mixture, or preparation contains one or more active medicinal  
426 ingredients not having a stimulant or depressant effect on the central nervous system, and if the  
427 admixtures are included therein in combinations, quantity, proportion, or concentration that  
428 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on  
429 the central nervous system.
- 430 7. The department of health and senior services shall place a substance in Schedule IV  
431 if it finds that:
- 432 (1) The substance has a low potential for abuse relative to substances in Schedule III;  
433 (2) The substance has currently accepted medical use in treatment in the United States;  
434 and
- 435 (3) Abuse of the substance may lead to limited physical dependence or psychological  
436 dependence relative to the substances in Schedule III.
- 437 8. The controlled substances listed in this subsection are included in Schedule IV:
- 438 (1) Any material, compound, mixture, or preparation containing any of the following  
439 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities  
440 as set forth below:
- 441 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms  
442 of atropine sulfate per dosage unit;
- 443 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-  
444 pFebruary 4, 2010ropionoxybutane);

445 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall  
446 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer  
447 upon the compound, mixture or preparation valuable medicinal qualities other than those  
448 possessed by the narcotic drug alone:

449 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per  
450 one hundred grams;

451 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters  
452 or per one hundred grams;

453 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters  
454 or per one hundred grams;

455 (2) Any material, compound, mixture or preparation containing any quantity of the  
456 following substances, including their salts, isomers, and salts of isomers whenever the existence  
457 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

458 (a) Alprazolam;

459 (b) Barbital;

460 (c) Bromazepam;

461 (d) Camazepam;

462 (e) Chloral betaine;

463 (f) Chloral hydrate;

464 (g) Chlordiazepoxide;

465 (h) Clobazam;

466 (i) Clonazepam;

467 (j) Clorazepate;

468 (k) Clotiazepam;

469 (l) Cloxazolam;

470 (m) Delorazepam;

471 (n) Diazepam;

472 (o) Dichloralphenazone;

473 (p) Estazolam;

474 (q) Ethchlorvynol;

475 (r) Ethinamate;

476 (s) Ethyl loflazepate;

477 (t) Fludiazepam;

478 (u) Flunitrazepam;

479 (v) Flurazepam;

480 (w) Halazepam;

- 481 (x) Haloxazolam;  
482 (y) Ketazolam;  
483 (z) Loprazolam;  
484 (aa) Lorazepam;  
485 (bb) Lormetazepam;  
486 (cc) Mebutamate;  
487 (dd) Medazepam;  
488 (ee) Meprobamate;  
489 (ff) Methohexital;  
490 (gg) Methylphenobarbital (mephobarbital);  
491 (hh) Midazolam;  
492 (ii) Nimetazepam;  
493 (jj) Nitrazepam;  
494 (kk) Nordiazepam;  
495 (ll) Oxazepam;  
496 (mm) Oxazolam;  
497 (nn) Paraldehyde;  
498 (oo) Petrichloral;  
499 (pp) Phenobarbital;  
500 (qq) Pinazepam;  
501 (rr) Prazepam;  
502 (ss) Quazepam;  
503 (tt) Temazepam;  
504 (uu) Tetrazepam;  
505 (vv) Triazolam;  
506 (ww) Zaleplon;  
507 (xx) Zolpidem;  
508 (yy) Zopiclone;  
509 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
510 following substance including its salts, isomers and salts of isomers whenever the existence of  
511 such salts, isomers and salts of isomers is possible: fenfluramine;  
512 (4) Any material, compound, mixture or preparation containing any quantity of the  
513 following substances having a stimulant effect on the central nervous system, including their  
514 salts, isomers and salts of isomers:  
515 (a) Cathine ((+)-norpseudoephedrine);  
516 (b) Diethylpropion;

- 517 (c) Fencamfamin;  
518 (d) Fenproporex;  
519 (e) Mazindol;  
520 (f) Mefenorex;  
521 (g) Modafinil;  
522 (h) Pemoline, including organometallic complexes and chelates thereof;  
523 (i) Phentermine;  
524 (j) Pipradrol;  
525 (k) Sibutramine;  
526 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);  
527 (5) Any material, compound, mixture or preparation containing any quantity of the  
528 following substance, including its salts:  
529 (a) butorphanol;  
530 (b) pentazocine;  
531 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance  
532 is the only active medicinal ingredient;  
533 (7) The department of health and senior services may except by rule any compound,  
534 mixture, or preparation containing any depressant substance listed in subdivision (1) of this  
535 subsection from the application of all or any part of sections 195.010 to 195.320 if the  
536 compound, mixture, or preparation contains one or more active medicinal ingredients not having  
537 a depressant effect on the central nervous system, and if the admixtures are included therein in  
538 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the  
539 substances which have a depressant effect on the central nervous system.  
540 9. The department of health and senior services shall place a substance in Schedule V  
541 if it finds that:  
542 (1) The substance has low potential for abuse relative to the controlled substances listed  
543 in Schedule IV;  
544 (2) The substance has currently accepted medical use in treatment in the United States;  
545 and  
546 (3) The substance has limited physical dependence or psychological dependence liability  
547 relative to the controlled substances listed in Schedule IV.  
548 10. The controlled substances listed in this subsection are included in Schedule V:  
549 (1) Any compound, mixture or preparation containing any of the following narcotic  
550 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set  
551 forth below, which also contains one or more nonnarcotic active medicinal ingredients in

552 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal  
553 qualities other than those possessed by the narcotic drug alone:

554 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than  
555 twenty-five micrograms of atropine sulfate per dosage unit;

556 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per  
557 one hundred grams;

558 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five  
559 micrograms of atropine sulfate per dosage unit;

560 (2) Any material, compound, mixture or preparation which contains any quantity of the  
561 following substance having a stimulant effect on the central nervous system including its salts,  
562 isomers and salts of isomers: pyrovalerone;

563 (3) Any compound, mixture, or preparation containing any detectable quantity of  
564 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,  
565 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical  
566 isomers, or salts of optical isomers;

567 (4) Unless specifically exempted or excluded or unless listed in another schedule, any  
568 material, compound, mixture, or preparation which contains any quantity of the following  
569 substances having a depressant effect on the central nervous system, including its salts:  
570 pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

571 11. If any compound, mixture, or preparation as specified in subdivision (3) of  
572 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a  
573 prescription:

574 (1) All packages of any compound, mixture, or preparation containing any detectable  
575 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,  
576 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind  
577 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or  
578 registered pharmacy technician; and

579 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,  
580 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,  
581 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers  
582 shall be at least eighteen years of age; and

583 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require  
584 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,  
585 or preparation to furnish suitable photo identification that is issued by a state or the federal  
586 government or a document that, with respect to identification, is considered acceptable and  
587 showing the date of birth of the person;

588 (4) The seller shall deliver the product directly into the custody of the purchaser.

589 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall  
590 implement and maintain an electronic log of each transaction. Such log shall include the  
591 following information:

592 (1) The name, address, and signature of the purchaser;

593 (2) The amount of the compound, mixture, or preparation purchased;

594 (3) The date and time of each purchase; and

595 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy  
596 technician who dispensed the compound, mixture, or preparation to the purchaser.

597 13. Each pharmacy shall submit information regarding sales of any compound, mixture,  
598 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with  
599 transmission methods and frequency established by the department by regulation;

600 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities  
601 greater than those specified in this chapter.

602 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products  
603 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter  
604 where the public is not permitted.

605 16. Any person who knowingly or recklessly violates the provisions of subsections 11  
606 to 15 of this section is guilty of a class A misdemeanor.

607 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this  
608 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,  
609 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,  
610 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must  
611 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

612 18. The manufacturer of a drug product or another interested party may apply with the  
613 department of health and senior services for an exemption from this section. The department of  
614 health and senior services may grant an exemption by rule from this section if the department  
615 finds the drug product is not used in the illegal manufacture of methamphetamine or other  
616 controlled or dangerous substances. The department of health and senior services shall rely on  
617 reports from law enforcement and law enforcement evidentiary laboratories in determining if the  
618 proposed product can be used to manufacture illicit controlled substances.

619 19. The department of health and senior services shall revise and republish the schedules  
620 annually.

621 20. The department of health and senior services shall promulgate rules under chapter  
622 536, RSMo, regarding the security and storage of Schedule V controlled substances, as described

623 in subdivision (3) of subsection 10 of this section, for distributors as registered by the department  
624 of health and senior services.

625 21. Logs of transactions required to be kept and maintained by this section and section  
626 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is  
627 the person whose transactions are recorded in the logs.

✓